"Analyst valuations
Following the positive Phase 3 trial results in December, the analysts covering Neuren significantly increased their current risk-adjusted valuations, with the range now $5.05 to $7.70 per share. In addition, Neuren was selected by Bioshares as one of the “Top 6 Picks for 2022” and was added to its model portfolio."
Ann: Q4 2021 quarterly activity and cash flow report, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.07 |
Change
0.110(0.52%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.95 | $792.7K | 37.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 761 | $21.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.13 | 107 | 4 |
View Market Depth
| Last trade - 10.18am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.79 |
Change
0.110 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.62 | 11075 | ||
| Last updated 10.37am 30/05/2024 ? | |||||
| NEU (ASX) Chart |